Show simple item record

dc.contributor.authorSargent, Jeremy T S
dc.contributor.authorSmith, Owen P
dc.date.accessioned2012-02-01T10:24:44Z
dc.date.available2012-02-01T10:24:44Z
dc.date.issued2012-02-01T10:24:44Z
dc.identifier.citationBr J Haematol. 2010 May;149(4):465-77. Epub 2010 Apr 4.en_GB
dc.identifier.issn1365-2141 (Electronic)en_GB
dc.identifier.issn0007-1048 (Linking)en_GB
dc.identifier.pmid20377591en_GB
dc.identifier.doi10.1111/j.1365-2141.2010.08173.xen_GB
dc.identifier.urihttp://hdl.handle.net/10147/207427
dc.description.abstractHypercalcaemia is a common metabolic complication of malignant disease often requiring emergency intervention. Although it is more frequently associated with solid tumours, malignancy-associated hypercalcaemia (MAH) is seen in a significant number of patients with blood diseases. Its association with myeloma and adult T-cell leukaemia/lymphoma is well recognized but the incidence of hypercalcaemia in other haematological neoplasms, affecting adults and children, is less clearly defined. Haematologists need to be familiar with the clinical manifestations of, the differential diagnosis to be considered and the most effective management strategies that are currently available for MAH. The key components of management of MAH include aggressive rehydration, specific therapy to inhibit bone resorption and, crucially, treatment of the underlying malignancy. Bisphosphonates have revolutionized the management of MAH over the last 20 years, however the elucidation of molecular pathways implicated in MAH is facilitating the development of more targeted approaches to treatment.
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshBone Density Conservation Agents/therapeutic useen_GB
dc.subject.meshChilden_GB
dc.subject.meshDiphosphonates/therapeutic useen_GB
dc.subject.meshFluid Therapy/methodsen_GB
dc.subject.meshHematologic Neoplasms/*complicationsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshHypercalcemia/diagnosis/*etiology/*therapyen_GB
dc.titleHaematological emergencies managing hypercalcaemia in adults and children with haematological disorders.en_GB
dc.contributor.departmentTrinity College, and Department of Haematology & Oncology, Our Lady's Children's , Hospital, Crumlin, Dublin, Ireland.en_GB
dc.identifier.journalBritish journal of haematologyen_GB
dc.description.provinceLeinster
html.description.abstractHypercalcaemia is a common metabolic complication of malignant disease often requiring emergency intervention. Although it is more frequently associated with solid tumours, malignancy-associated hypercalcaemia (MAH) is seen in a significant number of patients with blood diseases. Its association with myeloma and adult T-cell leukaemia/lymphoma is well recognized but the incidence of hypercalcaemia in other haematological neoplasms, affecting adults and children, is less clearly defined. Haematologists need to be familiar with the clinical manifestations of, the differential diagnosis to be considered and the most effective management strategies that are currently available for MAH. The key components of management of MAH include aggressive rehydration, specific therapy to inhibit bone resorption and, crucially, treatment of the underlying malignancy. Bisphosphonates have revolutionized the management of MAH over the last 20 years, however the elucidation of molecular pathways implicated in MAH is facilitating the development of more targeted approaches to treatment.


This item appears in the following Collection(s)

Show simple item record